In vivo expansion of the megakaryocyte progenitor cell population in adult CD26-deficient mice

Experimental Hematology

Volumn 39, Issue 5, 2011, Pages

  Kidd, Shannon ^a   Bueso Ramos, Carlos ^b   Jagan, Sucheta ^c   Paganessi, Laura A ^c   Boggio, Lisa N ^c   Fung, Henry C ^c   Gregory, Stephanie A ^c   Christopherson, Kent W ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW; CONTROLLED STUDY; ENZYME ACTIVITY; IN VIVO STUDY; MEGAKARYOBLAST; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL EXPANSION;

MUS;

EID: 79955149047     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2011.01.012     Document Type: Article

References (49)

1. Kaushansky K. Historical review: megakaryopoiesis and thrombopoiesis. Blood 2008, 111:981-986.
2. Akashi K., Traver D., Miyamoto T., Weissman I.L. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 2000, 404:193-197.
3. Nakorn T.N., Miyamoto T., Weissman I.L. Characterization of mouse clonogenic megakaryocyte progenitors. Proc Natl Acad Sci U S A 2003, 100:205-210.
4. Kaushansky K. Thrombopoietin. N Engl J Med 1998, 339:746-754.
5. Guerriero A., Worford L., Holland H.K., Guo G.R., Sheehan K., Waller E.K. Thrombopoietin is synthesized by bone marrow stromal cells. Blood 1997, 90:3444-3455.
6. Jelkmann W. The role of the liver in the production of thrombopoietin compared with erythropoietin. Eur J Gastroenterol Hepatol 2001, 13:791-801.
7. de Sauvage F.J., Hass P.E., Spencer S.D., et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994, 369:533-538.
8. Kaushansky K., Lok S., Holly R.D., et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994, 369:568-571.
9. Murone M., Carpenter D.A., de Sauvage F.J. Hematopoietic deficiencies in c-mpl and TPO knockout mice. Stem Cells 1998, 16:1-6.
10. Oppenheim J.J. Overview of chemokines. Adv Exp Med Biol 1993, 351:183-186.
11. Christopherson K., Hromas R. Chemokine regulation of normal and pathologic immune responses. Stem Cells 2001, 19:388-396.
12. Rojo D., Suetomi K., Navarro J. Structural biology of chemokine receptors. Biol Res 1999, 32:263-272.
13. Aiuti A., Webb I.J., Bleul C., Springer T., Gutierrez-Ramos J.C. The chemokine SDF-1 is a chemoattractant for human CD34 hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34progenitors to peripheral blood. J Exp Med 1997, 185:111-120.
14. Wright D.E., Bowman E.P., Wagers A.J., Butcher E.C., Weissman I.L. Hematopoietic stem cells are uniquely selective in their migratory response to chemokines. J Exp Med 2002, 195:1145-1154.
15. Christopherson K.W., Broxmeyer H.E. Hematopoietic stem and progenitor cell homing, engraftment, and mobilization in the context of the CXCL12/SDF-1-CXCR4 Axis. Cord Blood: Biology, Immunology, Banking, and Clinical Transplantation 2004, 65-86. AABB Press, Bethesda, MD. H.E. Broxmeyer (Ed.).
16. Peled A., Petit I., Kollet O., et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999, 283:845-848.
17. Avecilla S.T., Hattori K., Heissig B., et al. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med 2004, 10:64-71.
18. Minamiguchi H., Kimura T., Urata Y., et al. Simultaneous signalling through c-mpl, c-kit and CXCR4 enhances the proliferation and differentiation of human megakaryocyte progenitors: possible roles of the PI3-K, PKC and MAPK pathways. Br J Haematol 2001, 115:175-185.
19. Hodohara K., Fujii N., Yamamoto N., Kaushansky K. Stromal cell-derived factor-1 (SDF-1) acts together with thrombopoietin to enhance the development of megakaryocytic progenitor cells (CFU-MK). Blood 2000, 95:769-775.
20. Guerriero R., Mattia G., Testa U., et al. Stromal cell-derived factor 1alpha increases polyploidization of megakaryocytes generated by human hematopoietic progenitor cells. Blood 2001, 97:2587-2595.
21. Bongers J., Lambros T., Ahmad M., Heimer E.P. Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs. Biochim Biophys Acta 1992, 1122:147-153.
22. Vanham G., Kestens L., De Meester I., et al. Decreased expression of the memory marker CD26 on both CD4 and CD8T lymphocytes of HIV-infected subjects. J Acquir Immune Defic Syndr 1993, 6:749-757.
23. Kahne T., Lendeckel U., Wrenger S., Neubert K., Ansorge S., Reinhold D. Dipeptidyl peptidase IV: a cell surface peptidase involved in regulating T cell growth (review). Int J Mol Med 1999, 4:3-15.
24. Huhn J., Ehrlich S., Fleischer B., von Bonin A. Molecular analysis of CD26-mediated signal transduction in T cells. Immunol Lett 2000, 72:127-132.
25. Durinx C., Lambeir A.M., Bosmans E., et al. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem 2000, 267:5608-5613.
26. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999, 85:9-24.
27. Oravecz T., Pall M., Roderiquez G., et al. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med 1997, 186:1865-1872.
28. Schols D., Proost P., Struyf S., et al. CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity. Antiviral Res 1998, 39:175-187.
29. Proost P., De Meester I., Schols D., et al. Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J Biol Chem 1998, 273:7222-7227.
30. Proost P., Struyf S., Schols D., et al. Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha. FEBS Lett 1998, 432:73-76.
31. Shioda T., Kato H., Ohnishi Y., et al. Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc Natl Acad Sci U S A 1998, 95:6331-6336.
32. Van Coillie E., Proost P., Van Aelst I., et al. Functional comparison of two human monocyte chemotactic protein-2 isoforms, role of the amino-terminal pyroglutamic acid and processing by CD26/dipeptidyl peptidase IV. Biochemistry 1998, 37:12672-12680.
33. Struyf S., Proost P., Schols D., et al. CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. J Immunol 1999, 162:4903-4909.
34. Proost P., Struyf S., Schols D., et al. Truncation of macrophage-derived chemokine by CD26/dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J Biol Chem 1999, 274:3988-3993.
35. Iwata S., Yamaguchi N., Munakata Y., et al. CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES: possible mechanism for the switch from innate to acquired immune response. Int Immunol 1999, 11:417-426.
36. Proost P., Menten P., Struyf S., Schutyser E., De Meester I., Van Damme J. Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78beta into a most efficient monocyte attractant and CCR1 agonist. Blood 2000, 96:1674-1680.
37. Lambeir A.M., Proost P., Durinx C., et al. Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J Biol Chem 2001, 276:29839-29845.
38. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998, 392:565-568.
39. Christopherson K.W., Hangoc G., Broxmeyer H.E. Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34 progenitor cells. J Immunol 2002, 169:7000-7008.
40. Christopherson K.W., Cooper S., Broxmeyer H.E. Cell surface peptidase CD26/DPPIV mediates G-CSF mobilization of mouse progenitor cells. Blood 2003, 101:4680-4686.
41. Christopherson K.W., Cooper S., Hangoc G., Broxmeyer H.E. CD26 is essential for normal G-CSF-induced progenitor cell mobilization as determined by CD26-/- mice. Exp Hematol 2003, 31:1126-1134.
42. Christopherson K.W., Hangoc G., Mantel C.R., Broxmeyer H.E. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 2004, 305:1000-1003.
43. Marguet D., Baggio L., Kobayashi T., et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci U S A 2000, 97:6874-6879.
44. Wang J.F., Liu Z.Y., Groopman J.E. The alpha-chemokine receptor CXCR4 is expressed on the megakaryocytic lineage from progenitor to platelets and modulates migration and adhesion. Blood 1998, 92:756-764.
45. Hamada T., Mohle R., Hesselgesser J., et al. Transendothelial migration of megakaryocytes in response to stromal cell-derived factor 1 (SDF-1) enhances platelet formation. J Exp Med 1998, 188:539-548.
46. Riviere C., Subra F., Cohen-Solal K., et al. Phenotypic and functional evidence for the expression of CXCR4 receptor during megakaryocytopoiesis. Blood 1999, 93:1511-1523.
47. Kanamaru S., Kawano Y., Watanabe T., et al. Low numbers of megakaryocyte progenitors in grafts of cord blood cells may result in delayed platelet recovery after cord blood cell transplant. Stem Cells 2000, 18:190-195.
48. Nash R.A., Kurzrock R., DiPersio J., et al. A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2000, 6:25-34.
49. Schiffer C.A., Miller K., Larson R.A., et al. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood 2000, 95:2530-2535.